{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T01:19:03Z","timestamp":1766711943968,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10928-018-9600-2","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T06:51:31Z","timestamp":1531205491000},"page":"707-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Population pharmacokinetics\u2013pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-7372","authenticated-orcid":false,"given":"Fran\u00e7ois Pierre","family":"Combes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Baneyx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neva","family":"Coello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penny","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Sallas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hequn","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Nedelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"9600_CR1","doi-asserted-by":"crossref","unstructured":"Boulay A, Lane HA (2007) The mammalian target of rapamycin kinase and tumor growth inhibition. Recent Results Cancer Res Fortschr Krebsforsch Prog Dans Rech Sur Cancer 172:99\u2013124 .\n                    https:\/\/link.springer.com\/chapter\/10.1007%2F978-3-540-31209-3_7?LI=true\n                    \n                  . Accessed 7 July 2018","DOI":"10.1007\/978-3-540-31209-3_7"},{"issue":"2","key":"9600_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4103\/2319-4170.110365","volume":"36","author":"M Wong","year":"2013","unstructured":"Wong M (2013) Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomed J 36(2):40\u201350","journal-title":"Biomed J"},{"issue":"10056","key":"9600_CR3","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Lond Engl 388(10056):2153\u20132163","journal-title":"Lancet Lond Engl"},{"issue":"151\u2013155","key":"9600_CR4","first-page":"e1","volume":"172","author":"S J\u00f3\u017awiak","year":"2016","unstructured":"J\u00f3\u017awiak S, Kotulska K, Berkowitz N, Brechenmacher T, Franz DN (2016) Safety of everolimus in patients younger than 3 years of age: results from EXIST-1, a randomized, controlled clinical trial. J Pediatr 172(151\u2013155):e1","journal-title":"J Pediatr"},{"issue":"1","key":"9600_CR5","first-page":"111","volume":"31","author":"JJ Bissler","year":"2016","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E et al (2016) Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 31(1):111\u2013119","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc"},{"issue":"6","key":"9600_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0009-9236(03)00049-3","volume":"73","author":"R Miller","year":"2003","unstructured":"Miller R, Frame B, Corrigan B, Burger P, Bockbrader H, Garofalo E et al (2003) Exposure\u2013response analysis of pregabalin add-on treatment of patients with refractory partial seizures. Clin Pharmacol Ther 73(6):491\u2013505","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"9600_CR7","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1177\/0091270011407193","volume":"52","author":"JE Ahn","year":"2012","unstructured":"Ahn JE, Plan EL, Karlsson MO, Miller R (2012) Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment. J Clin Pharmacol 52(6):880\u2013892","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"9600_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10928-009-9132-x","volume":"36","author":"PL Bonate","year":"2009","unstructured":"Bonate PL, Sung C, Welch K, Richards S (2009) Conditional modeling of antibody titers using a zero-inflated Poisson random effects model: application to Fabrazyme. J Pharmacokinet Pharmacodyn 36(5):443\u2013459","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9600_CR9","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1038\/psp.2014.27","volume":"3","author":"EL Plan","year":"2014","unstructured":"Plan EL (2014) Modeling and simulation of count data. CPT Pharmacomet Syst Pharmacol 3:e129","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"5","key":"9600_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10928-009-9131-y","volume":"36","author":"IF Troc\u00f3niz","year":"2009","unstructured":"Troc\u00f3niz IF, Plan EL, Miller R, Karlsson MO (2009) Modelling overdispersion and Markovian features in count data. J Pharmacokinet Pharmacodyn 36(5):461\u2013477","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9861","key":"9600_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet Lond Engl 381(9861):125\u2013132","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"9600_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0010-4809(72)90051-1","volume":"5","author":"LB Sheiner","year":"1972","unstructured":"Sheiner LB, Rosenberg B, Melmon KL (1972) Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res Int J. 5(5):411\u2013459","journal-title":"Comput Biomed Res Int J."},{"issue":"3","key":"9600_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/cpt1979263294","volume":"26","author":"LB Sheiner","year":"1979","unstructured":"Sheiner LB, Beal S, Rosenberg B, Marathe VV (1979) Forecasting individual pharmacokinetics. Clin Pharmacol Ther 26(3):294\u2013305","journal-title":"Clin Pharmacol Ther"},{"key":"9600_CR14","volume-title":"NONMEM user\u2019s guide","author":"S Beal","year":"1989","unstructured":"Beal S, Sheiner LB, Boeckman A, Bauer R (1989) NONMEM user\u2019s guide. ICON Development Solutions, Ellicot City"},{"key":"9600_CR15","doi-asserted-by":"publisher","DOI":"10.1201\/b17203","volume-title":"Mixed effects models for the population approach: models, tasks, methods and tools","author":"M Lavielle","year":"2014","unstructured":"Lavielle M (2014) Mixed effects models for the population approach: models, tasks, methods and tools. Chapman and Hall, Boca Raton"},{"issue":"1","key":"9600_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10928-011-9228-y","volume":"39","author":"L Gibiansky","year":"2012","unstructured":"Gibiansky L, Gibiansky E, Bauer R (2012) Comparison of NONMEM 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model. J Pharmacokinet Pharmacodyn 39(1):17\u201335","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9600_CR17","unstructured":"Monolix user\u2019s guide. Lixoft, Antony. \n                    http:\/\/lixoft.com\/ressources\/"},{"issue":"3","key":"9600_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1067\/mcp.2001.118022","volume":"70","author":"JM Kovarik","year":"2001","unstructured":"Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C (2001) Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 70(3):247\u2013254","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"9600_CR19","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1007\/s11095-009-9931-1","volume":"26","author":"KJF Petersson","year":"2009","unstructured":"Petersson KJF, Hanze E, Savic RM, Karlsson MO (2009) Semiparametric distributions with estimated shape parameters. Pharm Res 26(9):2174\u20132185","journal-title":"Pharm Res"},{"issue":"1","key":"9600_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00228-004-0866-5","volume":"61","author":"JM Kovarik","year":"2005","unstructured":"Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL (2005) Effect of multiple-dose erythromycin on everolimus pharmacokinetics. Eur J Clin Pharmacol 61(1):35\u201338","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"9600_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2125.2005.02434.x","volume":"60","author":"JM Kovarik","year":"2005","unstructured":"Kovarik JM, Beyer D, Bizot MN, Jiang Q, Allison MJ, Schmouder RL (2005) Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol 60(4):434\u2013437","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"9600_CR22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1177\/0091270005275368","volume":"45","author":"JM Kovarik","year":"2005","unstructured":"Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL (2005) Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 45(5):514\u2013518","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"9600_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/0091270002042001011","volume":"42","author":"JM Kovarik","year":"2002","unstructured":"Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, Frazier OL, Rordorf C (2002) Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 42(1):95\u201399","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"9600_CR24","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1345\/aph.1A384","volume":"36","author":"JM Kovarik","year":"2002","unstructured":"Kovarik JM, Hartmann S, Figueiredo J, Rouilly M, Port A, Rordorf C (2002) Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 36(6):981\u2013985","journal-title":"Ann Pharmacother"},{"issue":"11","key":"9600_CR25","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1023\/A:1011940108365","volume":"15","author":"A Crowe","year":"1998","unstructured":"Crowe A, Lemaire M (1998) In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 15(11):1666\u20131672","journal-title":"Pharm Res"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-018-9600-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9600-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T02:38:02Z","timestamp":1569292682000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-018-9600-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["9600"],"URL":"https:\/\/doi.org\/10.1007\/s10928-018-9600-2","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"type":"print","value":"1567-567X"},{"type":"electronic","value":"1573-8744"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"assertion":[{"value":"8 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors are or were employees of Novartis at the time of the research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}